Does the media refer more to PURR or LNTH?

In the previous week, Hyperliquid Strategies had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 4 mentions for Lantheus. Hyperliquid Strategies' average media sentiment score of 0.81 beat Lantheus' score of 0.20 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PURR or SYRE more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Hyperliquid Strategies N/A -56.04% -52.22% Spyre Therapeutics N/A -42.88% -27.76%

Does the media refer more to PURR or SYRE?

In the previous week, Spyre Therapeutics had 3 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 8 mentions for Spyre Therapeutics and 5 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Spyre Therapeutics' score of -0.17 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PTCT or PURR?

In the previous week, PTC Therapeutics had 1 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 6 mentions for PTC Therapeutics and 5 mentions for Hyperliquid Strategies. PTC Therapeutics' average media sentiment score of 1.69 beat Hyperliquid Strategies' score of 0.81 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Hyperliquid Strategies 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or PURR?

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 5 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Protagonist Therapeutics' score of 0.78 indicating that Hyperliquid Strategies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RYTM or PURR?

In the previous week, Hyperliquid Strategies had 3 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 2 mentions for Rhythm Pharmaceuticals. Hyperliquid Strategies' average media sentiment score of 0.81 beat Rhythm Pharmaceuticals' score of 0.60 indicating that Hyperliquid Strategies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hyperliquid Strategies (PURR) Competitors

$8.53 -0.96 (-10.12%)

Closing price 04:00 PM Eastern

Extended Trading

$8.62 +0.09 (+1.00%)

As of 07:59 PM Eastern

Compare

PURR vs. LNTH, SYRE, PTCT, PTGX, and RYTM

Should you buy Hyperliquid Strategies stock or one of its competitors? MarketBeat compares Hyperliquid Strategies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperliquid Strategies include Lantheus (LNTH), Spyre Therapeutics (SYRE), PTC Therapeutics (PTCT), Protagonist Therapeutics (PTGX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does Hyperliquid Strategies compare to Lantheus?

Hyperliquid Strategies (NASDAQ:PURR) and Lantheus (NASDAQ:LNTH) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Hyperliquid Strategies has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Lantheus has higher revenue and earnings than Hyperliquid Strategies. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,232.16	-$16.01M	-$7.37	N/A
Lantheus	$1.54B	4.26	$233.56M	$4.15	24.33

Lantheus has a net margin of 18.05% compared to Hyperliquid Strategies' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Lantheus	18.05%	29.32%	15.00%

Hyperliquid Strategies presently has a consensus target price of $9.25, indicating a potential upside of 8.44%. Lantheus has a consensus target price of $101.86, indicating a potential upside of 0.87%. Given Hyperliquid Strategies' higher possible upside, equities research analysts plainly believe Hyperliquid Strategies is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Hyperliquid Strategies had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 4 mentions for Lantheus. Hyperliquid Strategies' average media sentiment score of 0.81 beat Lantheus' score of 0.20 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantheus beats Hyperliquid Strategies on 9 of the 15 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Spyre Therapeutics?

Hyperliquid Strategies (NASDAQ:PURR) and Spyre Therapeutics (NASDAQ:SYRE) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Hyperliquid Strategies has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 3 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 8 mentions for Spyre Therapeutics and 5 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Spyre Therapeutics' score of -0.17 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.5% of Hyperliquid Strategies shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 8.5% of Hyperliquid Strategies shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Hyperliquid Strategies presently has a consensus target price of $9.25, suggesting a potential upside of 8.44%. Spyre Therapeutics has a consensus target price of $91.33, suggesting a potential upside of 24.01%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spyre Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Hyperliquid Strategies has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,232.16	-$16.01M	-$7.37	N/A
Spyre Therapeutics	$890K	7,186.25	-$155.20M	-$2.08	N/A

Spyre Therapeutics' return on equity of -42.88% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Hyperliquid Strategies on 12 of the 15 factors compared between the two stocks.

How does Hyperliquid Strategies compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Hyperliquid Strategies has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Hyperliquid Strategies' return on equity of -56.04% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

9.5% of Hyperliquid Strategies shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PTC Therapeutics currently has a consensus target price of $89.00, indicating a potential upside of 25.41%. Hyperliquid Strategies has a consensus target price of $9.25, indicating a potential upside of 8.44%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

PTC Therapeutics has higher revenue and earnings than Hyperliquid Strategies. PTC Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.40	$682.64M	-$2.33	N/A
Hyperliquid Strategies	$1M	1,232.16	-$16.01M	-$7.37	N/A

In the previous week, PTC Therapeutics had 1 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 6 mentions for PTC Therapeutics and 5 mentions for Hyperliquid Strategies. PTC Therapeutics' average media sentiment score of 1.69 beat Hyperliquid Strategies' score of 0.81 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Hyperliquid Strategies	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PTC Therapeutics beats Hyperliquid Strategies on 10 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hyperliquid Strategies has lower revenue, but higher earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	136.08	-$130.15M	-$1.81	N/A
Hyperliquid Strategies	$1M	1,232.16	-$16.01M	-$7.37	N/A

Hyperliquid Strategies has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Protagonist Therapeutics currently has a consensus target price of $115.21, suggesting a potential upside of 18.31%. Hyperliquid Strategies has a consensus target price of $9.25, suggesting a potential upside of 8.44%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Protagonist Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 5 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.81 beat Protagonist Therapeutics' score of 0.78 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Hyperliquid Strategies on 11 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Hyperliquid Strategies has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Hyperliquid Strategies' return on equity of -56.04% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Hyperliquid Strategies has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	31.20	-$196.54M	-$3.13	N/A
Hyperliquid Strategies	$1M	1,232.16	-$16.01M	-$7.37	N/A

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Rhythm Pharmaceuticals currently has a consensus target price of $131.81, suggesting a potential upside of 52.56%. Hyperliquid Strategies has a consensus target price of $9.25, suggesting a potential upside of 8.44%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Rhythm Pharmaceuticals is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Hyperliquid Strategies had 3 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 2 mentions for Rhythm Pharmaceuticals. Hyperliquid Strategies' average media sentiment score of 0.81 beat Rhythm Pharmaceuticals' score of 0.60 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of Hyperliquid Strategies shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Rhythm Pharmaceuticals and Hyperliquid Strategies tied by winning 8 of the 16 factors compared between the two stocks.

Get Hyperliquid Strategies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PURR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PURR vs. The Competition

Export

Metric	Hyperliquid Strategies	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.37B	$2.93B	$4.24B	$11.97B
Dividend Yield	N/A	15.17%	7.93%	5.32%
P/E Ratio	N/A	13.61	21.75	23.66
Price / Sales	1,232.16	3,152.35	213.09	86.29
Price / Cash	N/A	28.12	53.68	55.53
Price / Book	5.61	5.91	27.92	6.39
Net Income	-$16.01M	-$40.08M	$109.80M	$337.36M
7 Day Performance	-14.61%	-1.93%	-3.42%	-3.07%
1 Month Performance	27.26%	0.04%	1.21%	0.37%
1 Year Performance	N/A	15.61%	12.95%	27.87%

Hyperliquid Strategies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PURR Hyperliquid Strategies	1.8631 of 5 stars	$8.53 -10.1%	$9.25 +8.4%	N/A	$1.37B	$1M	N/A	N/A	Analyst Upgrade Options Volume Gap Down
LNTH Lantheus	2.0205 of 5 stars	$96.30 -0.9%	$101.86 +5.8%	+29.1%	$6.32B	$1.54B	23.20	1,193
SYRE Spyre Therapeutics	2.1438 of 5 stars	$69.16 -2.0%	$90.25 +30.5%	+375.1%	$6.13B	$890K	N/A	73	News Coverage Analyst Forecast Insider Trade
PTCT PTC Therapeutics	3.6443 of 5 stars	$68.23 -7.5%	$89.00 +30.4%	+38.2%	$6.12B	$1.73B	N/A	1,410	Positive News
PTGX Protagonist Therapeutics	2.5731 of 5 stars	$93.19 -1.8%	$115.21 +23.6%	+99.5%	$6.10B	$46.02M	N/A	120	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PURR) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperliquid Strategies (PURR) Competitors

PURR vs. LNTH, SYRE, PTCT, PTGX, and RYTM

How does Hyperliquid Strategies compare to Lantheus?

Summary

How does Hyperliquid Strategies compare to Spyre Therapeutics?

Summary

How does Hyperliquid Strategies compare to PTC Therapeutics?

Summary

How does Hyperliquid Strategies compare to Protagonist Therapeutics?

Summary

How does Hyperliquid Strategies compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperliquid Strategies (PURR) Competitors

PURR vs. LNTH, SYRE, PTCT, PTGX, and RYTM

How does Hyperliquid Strategies compare to Lantheus?

Which has more volatility and risk, PURR or LNTH?

Which has higher earnings & valuation, PURR or LNTH?

Is PURR or LNTH more profitable?

Do analysts recommend PURR or LNTH?

Do institutionals and insiders believe in PURR or LNTH?

Does the media refer more to PURR or LNTH?

Summary

How does Hyperliquid Strategies compare to Spyre Therapeutics?

Which has more risk & volatility, PURR or SYRE?

Does the media refer more to PURR or SYRE?

Do insiders and institutionals hold more shares of PURR or SYRE?

Do analysts recommend PURR or SYRE?

Which has higher valuation and earnings, PURR or SYRE?

Is PURR or SYRE more profitable?

Summary

How does Hyperliquid Strategies compare to PTC Therapeutics?

Which has more risk and volatility, PTCT or PURR?

Is PTCT or PURR more profitable?

Do insiders & institutionals believe in PTCT or PURR?

Do analysts prefer PTCT or PURR?

Which has stronger valuation and earnings, PTCT or PURR?

Does the media refer more to PTCT or PURR?

Summary

How does Hyperliquid Strategies compare to Protagonist Therapeutics?

Which has more risk & volatility, PTGX or PURR?

Do institutionals and insiders hold more shares of PTGX or PURR?

Which has better earnings & valuation, PTGX or PURR?

Is PTGX or PURR more profitable?

Do analysts rate PTGX or PURR?

Does the media prefer PTGX or PURR?

Summary

How does Hyperliquid Strategies compare to Rhythm Pharmaceuticals?

Is RYTM or PURR more profitable?

Which has better earnings & valuation, RYTM or PURR?

Which has more risk & volatility, RYTM or PURR?

Do analysts rate RYTM or PURR?

Does the media prefer RYTM or PURR?

Do institutionals and insiders hold more shares of RYTM or PURR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools